What methods evaluated polivy's treatment effectiveness?

Polivy (polatuzumab vedotin) effectiveness was evaluated in a few key clinical studies, most importantly:

1. Randomized controlled trial (GO29834 / “Polivy + bendamustine + rituximab” vs standard)

• Design: Phase 2, randomized, with an active control.
• Comparison groups (in the main efficacy analysis):
  • Polivy + bendamustine + rituximab (BR)
  • vs bendamustine + rituximab (BR) alone
• Main effectiveness endpoints:
  • Overall response rate (ORR) assessed by imaging criteria
  • Duration of response (DOR)
  • Progression-free survival (PFS)
  • Overall survival (OS)

2. Study supporting data in DLBCL (study CA165-019 / single‑arm)

• Design: Phase 1b/2, commonly single‑arm or investigator-chosen comparator context (not randomized for the primary efficacy comparison).
• Main effectiveness endpoints:
  • ORR (again based on radiographic response criteria)
  • DOR and other time-to-event outcomes

How “effectiveness” was measured (methods/endpoints)

Across these trials, the treatment effect was evaluated using:

• Radiographic tumor response using standardized response criteria (e.g., Lugano/RECIST-style methods as applicable)
• Time-to-event outcomes:
  • PFS and OS (with Kaplan–Meier methods and hazard ratios typically reported)
  • DOR
• Response categories:
  • Complete response (CR) and partial response (PR) contributing to ORR

If you tell me which patient population you mean (e.g., relapsed/refractory DLBCL after at least one prior therapy), I can point to the exact trial(s) and list the endpoints used in that specific analysis.